Results 151 to 160 of about 22,676 (187)

Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study. [PDF]

Ann Hematol
Li Y, Shang Y, Liu K, Liu Y, Lin D, He J, Li J, Zeng Y, Wei H, Yan Z, Mi Y.   +10 more
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Monitoring Variant Allele Fraction in VEXAS Syndrome: A Comparison of Digital PCR and Next-Generation Sequencing. [PDF]

EJHaem
Exposito-Bey A, Montes-Cano MA, Payán-Pernía S, García-Lozano JR, González-Escribano MF.   +4 more
europepmc   +1 more source

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy. [PDF]

Blood Adv
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD.   +28 more
europepmc   +1 more source

Combined anti-tumor effects of metformin and azacitidine in breast cancer cells. [PDF]

BMC Cancer
Hosseini SS, Askari N, Yaghoobi MM.
europepmc   +1 more source

Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine. [PDF]

Cancer
Buchrits S, Rozental A, Korngold N, Algor O, Partouche S, Granot G, Raanani P, Wolach O.   +7 more
europepmc   +1 more source

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review. [PDF]

Ann Hematol
Ng JY, Gullapalli V, Othman J, Talaulikar D.   +3 more
europepmc   +1 more source